HD-OPM Archive
Topics › Kidney health

SGLT2 inhibitors slow CKD progression regardless of diabetes status, per meta-analyses

Louis Nervegna · Jan 20, 2026 · ♥ 8 reactions · 0 comments · original Facebook post
Kidney healthInsulin resistance & diabetes
AI summary & key facts

Louis shares a JAMA editorial: meta-analyses show SGLT2 inhibitors consistently reduce kidney disease progression and hospitalizations across eGFR and albuminuria subgroups, regardless of diabetes.

Meta-analyses of randomized trials show SGLT2 inhibitor drugs slow progression of chronic kidney disease.

It’s becoming clear that this class of drugs does much more than just treat diabetes.

Chronic kidney disease is a major risk factor for heart disease.

Slowing its progression not only protects the kidneys, but the whole cardiovascular system as well.

#sglt2HD #diabetesHD #ckdHD #kidneysHD

Research cited

Shared from JAMA · original post

💬 Editorial: Meta-analyses showed #SGLT2 inhibitors consistently reduce #KidneyDisease progression and hospitalizations across all eGFR and albuminuria subgroups, regardless of #diabetes status.

These benefits persisted among patients with advanced CKD or low albuminuria, supporting broader eligibility and use.

Paper · JAMA · 2026Time for Broader Adoption of SGLT2 Inhibitors in Clinical Practice?jamanetwork.comNo photo description available.
← newer: MIND diet: Mediterranean-DASH hybrid for brain healtholder: Harvard begins clinical trials of low-dose lithium for Alzhe →